Taxane-induced peripheral neuropathy more common in patients with diabetes longer than 5 years
the ONA take:
Patients receiving taxane-based therapy who have had diabetes for more than 5 years may be at a higher risk for developing severe peripheral sensory neuropathy, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
For the study, researchers in Turkey sought to determine whether the presence of diabetes mellitus impacts the incidence and severity of peripheral sensory neuropathy in patients undergoing taxane therapy for cancer. Researchers retrospectively analyzed data from 374 patients receiving taxane therapy at a single institution. Of those, 21.6% had diabetes.
Results showed that the incidence of grade 1 peripheral neuropathy in patients receiving taxane-based therapy was 33.4% in non-diabetics and 25.9% in those with diabetes; however, the incidence of grade 2 or higher peripheral neuropathy was 15% and 34.6%, respectively.
Researchers found that the overall incidence of peripheral neuropathy was 48.8% in non-diabetic patients, 52.8% in patients with diabetes less than 5 years, and 75% in patients with diabetes for longer than 5 years.
Patients receiving taxane-based therapy who have had diabetes for more than 5 years may be at a higher risk for neuropathy.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Neuropathic Cancer Pain Linked to Reduced Quality of Life
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|